Skip to main content

Table 1 Immunoreactive protein spots identified by MALDI-TOF-MS

From: Identification of putative biomarkers for the serodiagnosis of drug-resistant Mycobacterium tuberculosis

Spot Noa.

NCBI accession no.b

Sanger I.D.

Protein identification

MW/PI

Mascot scorec

GRAVY scored

2D immunoreactivity

    

Theoretical

Experimental

  

Sensitive M. tuberculosis

RIF r M. tuberculosis

MDR M. tuberculosis

M1

gi|1322434

Rv1310

ATP synthase beta chain (atpD)

53093.32/4.76

53061.2/4.86

433, 57

-0.168

S-serae

All sera

All sera

M2

gi|2916918

Rv0859c

Acyl-CoA thiolase (fadA)

42413.60/5.14

42387.8/5.2

181, 32

0.035

R-sera

--

--

M3

gi|15610828

Rv3692

Methanol dehydrogenase regulatory protein(moxR2)

37903.47/5.51

37904.3/5.43

192, 20

-0.002

--

R-sera

--

M4

gi|15610165

Rv3028c

electron transfer flavoprotein (alpha subunit) (fixB, etfA)

31690.02/4.61

31699.8/4.47

746, 68

0.358

--

--

R-sera

M5

gi|2791638

Rv3040

Conserved hypothetical protein

31484.26/4.50

31465.7/4.65

98, 6

-0.297

--

--

R-sera

M6

gi|2104333

Rv2145c

antigen 84(wag31)

28276.23/4.75

28260.1/4.80

133, 49

-0.726

--

--

R-sera

M7

gi|15607779

Rv0639

Transcription antitermination protein(nusG)

25413.54/4.59

25431.0/4.70

175, 23

-0.180

--

--

R-sera

M8

gi|15607585

Rv0444c

Conserved hypothetical protein

23882.15/5.82

23883.0/5.81

75, 13

0.062

--

R-sera

--

S1

gi|2896768

Rv2031c

Heat Shock Protein hspX (14-kDa antigen)

16226.30/4.90

16217.2/5.0

209, 35

-0.52

--

S-sera

--

  1. a) Spot numbers refer to the numbers on the 2-DE gels showed in Figure 1A-C.
  2. b) Accession no. obtained from the MASCOT results of MALDI-TOF/TOF from the NCBInr database http://www.ncbi.nlm.nih.gov.
  3. c) MASCOT score and percent sequence coverage of all tryptic peptides identified by MALDI-TOF-MS/MS. MASCOT protein scores (based on combined MS and MS/MS spectra (Additional files 1, 2, 3, 4, 5, 6, 7 and 8) greater than 72 were considered statistically significant (p ≤ 0.05).
  4. d) Grand average of hydropathy.
  5. e) Anti-sera from TB patients infected with antibiotic-sensitive M. tuberculosis.
  6. f) Anti-sera from TB patients infected with drug-resistant M. tuberculosis